Cargando…
Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998558/ https://www.ncbi.nlm.nih.gov/pubmed/29895329 http://dx.doi.org/10.1186/s13104-018-3481-8 |
_version_ | 1783331252633337856 |
---|---|
author | Ovesen, Christian Jakobsen, Janus Christian Gluud, Christian Steiner, Thorsten Law, Zhe Flaherty, Katie Dineen, Rob A. Bath, Philip M. Sprigg, Nikola Christensen, Hanne |
author_facet | Ovesen, Christian Jakobsen, Janus Christian Gluud, Christian Steiner, Thorsten Law, Zhe Flaherty, Katie Dineen, Rob A. Bath, Philip M. Sprigg, Nikola Christensen, Hanne |
author_sort | Ovesen, Christian |
collection | PubMed |
description | OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to spot sign negative patients. The TICH-2 trial recruited above 2000 participants with intracerebral haemorrhage arriving in hospital within 8 h after symptom onset. They were included irrespective of radiological signs of on-going haematoma expansion. Participants were randomised to tranexamic acid versus matching placebo. In this subgroup analysis, we will include all participants in TICH-2 with a computed tomography angiography on admission allowing adjudication of the participants’ spot sign status. RESULTS: Primary outcome will be the ability of tranexamic acid to limit absolute haematoma volume on computed tomography at 24 h (± 12 h) after randomisation among spot sign positive and spot sign negative participants, respectively. Within all outcome measures, the effect of tranexamic acid in spot sign positive/negative participants will be compared using tests of interaction. This sub-study will investigate the important clinical hypothesis that spot sign positive patients might benefit more from administration of tranexamic acid compared to spot sign negative patients. Trial registration ISRCTN93732214 (http://www.isrctn.com) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-018-3481-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5998558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59985582018-06-25 Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial Ovesen, Christian Jakobsen, Janus Christian Gluud, Christian Steiner, Thorsten Law, Zhe Flaherty, Katie Dineen, Rob A. Bath, Philip M. Sprigg, Nikola Christensen, Hanne BMC Res Notes Research Note OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to spot sign negative patients. The TICH-2 trial recruited above 2000 participants with intracerebral haemorrhage arriving in hospital within 8 h after symptom onset. They were included irrespective of radiological signs of on-going haematoma expansion. Participants were randomised to tranexamic acid versus matching placebo. In this subgroup analysis, we will include all participants in TICH-2 with a computed tomography angiography on admission allowing adjudication of the participants’ spot sign status. RESULTS: Primary outcome will be the ability of tranexamic acid to limit absolute haematoma volume on computed tomography at 24 h (± 12 h) after randomisation among spot sign positive and spot sign negative participants, respectively. Within all outcome measures, the effect of tranexamic acid in spot sign positive/negative participants will be compared using tests of interaction. This sub-study will investigate the important clinical hypothesis that spot sign positive patients might benefit more from administration of tranexamic acid compared to spot sign negative patients. Trial registration ISRCTN93732214 (http://www.isrctn.com) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-018-3481-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-13 /pmc/articles/PMC5998558/ /pubmed/29895329 http://dx.doi.org/10.1186/s13104-018-3481-8 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Note Ovesen, Christian Jakobsen, Janus Christian Gluud, Christian Steiner, Thorsten Law, Zhe Flaherty, Katie Dineen, Rob A. Bath, Philip M. Sprigg, Nikola Christensen, Hanne Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial |
title | Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial |
title_full | Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial |
title_fullStr | Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial |
title_full_unstemmed | Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial |
title_short | Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial |
title_sort | prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the tich-2 trial |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998558/ https://www.ncbi.nlm.nih.gov/pubmed/29895329 http://dx.doi.org/10.1186/s13104-018-3481-8 |
work_keys_str_mv | AT ovesenchristian preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT jakobsenjanuschristian preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT gluudchristian preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT steinerthorsten preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT lawzhe preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT flahertykatie preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT dineenroba preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT bathphilipm preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT spriggnikola preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial AT christensenhanne preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial |